 |
|
|
|
November 2004 Cover
|
|
Despite widespread praise of Fuzeon's effectiveness, the AIDS drug has been afflicted by disappointing sales, bad reaction to the $20,000 per-patient annual price, needle fears among patients, and early manufacturing difficulties since its March 2003 Food and Drug
Administration approval. Now, a September 3 report says that irritation caused by injecting the drug is likely to limit Fuzeon's use for some patients to two or three years because patients will "eventually run out of skin surface for injection."
Trimeris is addressing adverse reactions to Fuzeon injections. The company plans to initiate a "needle-free" method of administering Fuzeon next year. Trimeris is evaluating pneumatic delivery systems currently in use for vaccines, insulin and multiple sclerosis
treatments. In addition, Trimeris and Roche have begun to provide patients training on proper injection methods.
Editor's Note: from the News & Observer (Raleigh, NC)
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
